CALQUENCE®▼ (acalabrutinib)
CALQUENCE® (acalabrutinib) is een remmer van het Bruton Tyrosine Kinase (BTK)
voor de behandeling van chronische lymfatische leukemie (CLL).1
Team
Uw contactpersonen
Stéphane Lemaire
Hospital Representative
Hematology
& Gastrointestinal Oncology
Wallonia & Luxembourg
Het bredere team Hematology
Tom Ghysels
Business Unit Director
Oncology & Hematology
Joeri Van Op den Bosch
Franchise Lead
Hematology
& Gastrointestinal Oncology
Thierry Marysael
Medical Affairs Lead
Hematolog/Breast
& ovarian cancer
Maureen Van Well
Government Affairs &
Market Access Lead
Oncology
Tine Cuppens
Medical Affairs Manager
Hematology
Zakaria Bouzaiane
Brand Manager
Hematology
& Gastrointestinal Oncology
Marieke Siemons
First Line Sales Manager
Hematology
& Gastrointestinal Oncology